At the time of writing, Avidity Biosciences Inc [RNA] stock is trading at $70.68, down -0.17%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RNA shares have gain 1.20% over the last week, with a monthly amount glided 47.59%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on September 17, 2025, when Roth Capital initiated its Buy rating and assigned the stock a price target of $62. On June 24, 2025, Bernstein initiated with an Outperform rating and assigned a price target of $50 on the stock. Wolfe Research started tracking the stock assigning an Outperform rating and suggested a price target of $55 on June 17, 2025. Raymond James initiated its recommendation with a Strong Buy and recommended $65 as its price target on June 11, 2025. Citigroup started tracking with a Buy rating for this stock on March 13, 2025, and assigned it a price target of $70. In a note dated March 12, 2025, BMO Capital Markets initiated an Outperform rating and provided a target price of $72 on this stock.
For the past year, the stock price of Avidity Biosciences Inc fluctuated between $21.51 and $71.09. Currently, Wall Street analysts expect the stock to reach $74.44 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $70.68 at the most recent close of the market. An investor can expect a potential return of 5.32% based on the average RNA price forecast.
Analyzing the RNA fundamentals
According to Avidity Biosciences Inc [NASDAQ:RNA], the company’s sales were 20.87M for trailing twelve months, which represents an 434.03% jump. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -48.63%, Pretax Profit Margin comes in at -42.48%, and Net Profit Margin reading is -42.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.33 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 70.44 points at the first support level, and at 70.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 70.98, and for the 2nd resistance point, it is at 71.28.
Ratios To Look Out For
It is important to note that Avidity Biosciences Inc [NASDAQ:RNA] has a current ratio of 11.57. Also, the Quick Ratio is 11.57, while the Cash Ratio stands at 1.81. Considering the valuation of this stock, the price to sales ratio is 510.29, the price to book ratio is 5.50.
Transactions by insiders
Recent insider trading involved Hughes Steven George, Chief Medical Officer, that happened on Oct 22 ’25 when 2209.0 shares were sold. Chief Human Resources Officer, McCarthy Teresa completed a deal on Oct 15 ’25 to sell 20000.0 shares. Meanwhile, Chief Commercial Officer Mosbrooker Eric sold 6562.0 shares on Oct 03 ’25.
